Maquindox Veterinary Grade API is released as a crystalline active substance belonging to the quinoxaline-N,N′-dioxide class, intended for downstream manufacture of tablets, injections, capsules, powders, granules, premixes, and solutions. The veterinary-grade designation requires manufacture under a current GMP framework aligned with ICH Q7, with batch release against a certificate of analysis covering identity, assay, related substances, residual solvents, elemental impurities, and specified physical attributes. Two standard physical grades are supplied: a micronized grade for low-dose solid oral dosage forms where content uniformity under Ph. Eur. 2.9.40 is critical, and a granular grade for premix and powder blending where dust containment and flowability dominate. Particle-size targets are agreed between manufacturer and dosage-form producer; a commonly specified target for the micronized grade is D90 ≤ 30 µm, while the granular grade is typically controlled to D90 ≤ 250 µm with a defined fines limit to reduce segregation.

Grade designations are physical rather than chemical: micronized grade for tablets and capsules, granular grade for premix and powders, and low-endotoxin grade for injections. The model code therefore reflects particle-size and endotoxin-control requirements of the target dosage form rather than a change in active substance identity. Storage is specified as cool, dry, and light-protected; a common maximum storage temperature is 25°C, and the original manufacturer typically assigns a retest period of 24 months when the unopened container is stored in the original vapour-barrier bag.

What distinguishes the quinoxaline-N,N′-dioxide pharmacophore during granulation?

The granulation behaviour of Maquindox is governed less by particle morphology than by the reduction-sensitive N-oxide groups. In high-shear wet granulation, contact with unpassivated steel and reducing agents should be excluded; product-contact surfaces are typically specified as 316L stainless steel with passivation records. Binder solutions are prepared in demineralised water with conductivity below 5 µS/cm to reduce the risk of ionic interactions. Aqueous granulation with sodium carboxymethylcellulose or pregelatinised starch commonly supports a wet mass loss-on-drying endpoint of 2.0–3.5%, but residence time above 60 min should be avoided without supporting stability data. Published thermodynamic stability data specific to Maquindox under these granulation conditions are limited; therefore, each formulation is subjected to a forced-degradation matrix following VICH GL3 before scale-up.

Specification envelope for veterinary-grade Maquindox

Table 1 presents a representative release specification for the micronized veterinary grade. The acceptance criteria are aligned with general chapters of the Ph. Eur. and USP applicable to active substances for veterinary use; buyer specifications may be tightened where a national monograph or marketing authorisation file imposes additional controls.

For tablets and capsules, the micronized grade is dispersed into a dry premix containing microcrystalline cellulose, maize starch, and croscarmellose sodium before aqueous granulation or direct compression. Direct compression is limited to low-dose strengths where the API content is below 5.0% of the tablet weight and the excipient system has been proven to give a blend relative standard deviation below 5.0%. Above that dose, wet granulation is more robust because it prevents segregation of the high-density API particles. For compressed tablets, the target in-process parameters typically include a crushing strength of 40–80 N, friability below 0.8%, and disintegration time below 15 min in water at 37°C. For capsules, the granule bulk density is controlled to 0.45–0.65 g/mL to ensure reproducible filling on intermittent-motion capsule machines without excessive compaction. Film-coated tablets may be required if photostability studies under VICH GL5 demonstrate significant degradation; aluminium/aluminium blisters provide additional protection.

Compatibility screening should include lactose, starch, cellulose, dicalcium phosphate, and magnesium stearate. Lactose in alkaline granulation or at high temperature can act as a reducing sugar; the N-oxide functionality is susceptible to reduction, leading to colour change and assay loss. Dicalcium phosphate anhydrous is generally preferred over lactose in wet granulation when alkaline microenvironments are created by sodium starch glycolate. Magnesium stearate at levels above 1.0% can delay disintegration if blend mixing is prolonged above 5 min; therefore, lubricant mixing time is limited and the specific surface area of the API is controlled.

When aqueous granulation replaces direct compression in premix manufacture

Premix production for veterinary feed application frequently uses adsorption onto a carrier rather than true granulation. The granular grade is blended with carriers such as ground maize meal, rice hulls, or calcium carbonate in a ribbon blender. Fill volume is maintained at 50–70% of working capacity to avoid dead zones; mixing time is typically 10–15 min after an initial geometric dilution step. If the premix is subsequently wetted for granulation, the carrier moisture must remain below 5.0% because retained water accelerates N-oxide reduction. A final premix should be sieved through a 0.8–1.0 mm mesh to remove soft agglomerates before packaging in multi-wall paper sacks with an inner polyethylene liner. The bulk density of the finished premix is usually controlled to 0.55–0.70 g/mL to maintain metering accuracy in feed mills.

In aqueous injection manufacture, the low-endotoxin grade is dissolved in Water for Injection with pH adjustment; citrate or acetate buffers in the pH 4.0–5.5 range are commonly screened because solubility and degradation rate are both pH-dependent. The solution is blanketed with nitrogen if headspace oxygen exceeds 2.0%, and light-shielded manufacturing areas are used when photostability screening under VICH GL5 indicates sensitivity. Terminal sterilisation at 121°C for 15 min is only acceptable when the manufacturer has demonstrated thermal stability and no assay loss greater than 2.0%; otherwise, filtration through a 0.22 µm sterilising-grade membrane is used in an aseptic process validated to Ph. Eur. 5.1.1. The primary package is generally amber Type I glass, with headspace nitrogen and a chlorobutyl stopper. For multi-dose solutions, antimicrobial preservation testing under Ph. Eur. 5.1.3 is mandatory, and the selected preservative must be checked for incompatibility with the N-oxide group.

Comparative handling against carbadox, olaquindox, and standard antibiotic premixes

Maquindox belongs to the same quinoxaline-N,N′-dioxide family as carbadox and olaquindox, but the substitution pattern on the quinoxaline core alters the reversed-phase retention time, the solubility profile, and the sensitivity to alkaline hydrolysis. These differences do not permit direct interchange of the APIs in a licensed formulation; a change would require revalidation of the manufacturing process and dissolution or feed stability data. Published residue depletion and tissue metabolism data for Maquindox are less extensive than for the older quinoxaline compounds; therefore, maximum residue limit status must be confirmed for each target market. Comparative regulatory data show that olaquindox is not authorised as a feed additive in the European Union, carbadox is subject to restricted-use programs in certain jurisdictions, and Maquindox may be controlled under separate national registration schemes. The differences are primarily regulatory and process-specific rather than an indication of equivalent clinical performance.

Analytical method transfer from older quinoxaline APIs should not be assumed. The reversed-phase HPLC method for carbadox or olaquindox may require a lower organic modifier content or an alternative column temperature because the acetyl substituent on Maquindox shifts retention and peak symmetry. During cleaning verification, the selected wavelength must be reoptimised; otherwise, residual API peaks may coelute with common preservatives such as methyl paraben. The method detection limit should be established as at least 0.05 µg/mL, and the quantitation limit should not exceed 0.15 µg/mL when the carryover criterion is 10 ppm.

For oral powders and granules, the granular grade is dry-blended with dextrose or lactose vehicles, but the choice of lactose requires a reducing-sugar compatibility study because the N-oxide group can be chemically reduced under heat and moisture. Flavours and sweeteners are incorporated after the API blend is uniform; mixing is stopped when the relative standard deviation of three thief samples is below 5.0% by HPLC. The resulting powder is filled into sachets or jars with desiccant, and the package is labelled to protect from light. For oral solutions, a concentrated solution may be manufactured by dissolving the API in a co-solvent system such as propylene glycol and purified water; pH adjustment is performed at low temperature to minimise degradation. The finished solution is filled under nitrogen and stored in amber bottles. Because Maquindox is a potent antibacterial agent, cleaning validation after solution manufacture uses a worst-case carryover limit not exceeding 10 ppm of the subsequent batch size, with analytical verification by HPLC.

Premix and powder production lines handling Maquindox require dust containment because the granular grade generates respirable fines during transfer. Local exhaust ventilation and high-efficiency air filtration are specified at the dispensing station, and operators use suitable respiratory protection. Equipment cleaning is verified by rinse or swab sampling with an HPLC limit of detection below 0.1 µg/mL; cross-contamination limits are derived from the toxicological profile and the subsequent product batch size. These controls are especially critical when the same line processes other veterinary antibiotics, because the quinoxaline-N,N′-dioxide chromophore is detectable at low levels and can be differentiated from sulfonamide or tetracycline residues by the established HPLC method.